Northwestern Mutual Wealth Management Co. Acquires 100,968 Shares of Medpace Holdings, Inc. $MEDP

Northwestern Mutual Wealth Management Co. increased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 24,930.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 101,373 shares of the company’s stock after purchasing an additional 100,968 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Medpace were worth $56,936,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Quent Capital LLC bought a new stake in Medpace in the third quarter worth $25,000. Optiver Holding B.V. bought a new stake in Medpace in the third quarter worth $27,000. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace in the fourth quarter worth $30,000. Finally, Quarry LP bought a new stake in Medpace in the third quarter worth $35,000. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MEDP shares. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. BMO Capital Markets reduced their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Truist Financial reduced their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Mizuho set a $582.00 price target on shares of Medpace in a research report on Wednesday, February 11th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $467.08.

Medpace Price Performance

NASDAQ:MEDP opened at $415.27 on Monday. Medpace Holdings, Inc. has a 1-year low of $287.17 and a 1-year high of $628.92. The company has a 50-day moving average of $463.68 and a 200 day moving average of $524.55. The firm has a market cap of $11.86 billion, a PE ratio of 26.10, a price-to-earnings-growth ratio of 2.11 and a beta of 1.19.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms issued fresh reminders about an already filed class action alleging Medpace misled investors during the April 22, 2025 to February 9, 2026 period, with lead-plaintiff deadlines approaching in early June. Article Title
• Negative Sentiment: New and repeated class-action notices are keeping Medpace’s alleged investor-harm claims in the spotlight, which can weigh on sentiment and increase legal overhang for the stock. Article Title
• Negative Sentiment: Coverage specifically highlighting Medpace’s backlog disclosures and governance suggests investors are scrutinizing the quality of the company’s operational reporting, adding to uncertainty around future performance. Article Title
• Negative Sentiment: Additional law firm notices from Faruqi & Faruqi, The Gross Law Firm, BFA Law, Rosen, Pomerantz, DJS Law Group, and Schall keep the class action front and center, reinforcing a negative near-term narrative for MEDP. Article Title

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.